IN2012CH05549A - - Google Patents

Download PDF

Info

Publication number
IN2012CH05549A
IN2012CH05549A IN5549CH2012A IN2012CH05549A IN 2012CH05549 A IN2012CH05549 A IN 2012CH05549A IN 5549CH2012 A IN5549CH2012 A IN 5549CH2012A IN 2012CH05549 A IN2012CH05549 A IN 2012CH05549A
Authority
IN
India
Prior art keywords
composition
ibuprofen
pharmaceutically acceptable
acceptable salt
active ingredient
Prior art date
Application number
Other languages
English (en)
Inventor
Prodduturi Dr Suneela
Chandra Illapakurthy Dr Ashok
Kumar Alluri Pavan
Kandarapu Dr Raghupathi
S Rudraraju Dr Varma
Original Assignee
Aizant Drug Res Solution Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aizant Drug Res Solution Private Ltd filed Critical Aizant Drug Res Solution Private Ltd
Priority to PCT/IB2013/061370 priority Critical patent/WO2014102745A1/fr
Priority to IN5549CH2012 priority patent/IN2012CH05549A/en
Publication of IN2012CH05549A publication Critical patent/IN2012CH05549A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
IN5549CH2012 2012-12-31 2013-12-27 IN2012CH05549A (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/061370 WO2014102745A1 (fr) 2012-12-31 2013-12-27 Composition d'ibuprofène à libération prolongée à forte charge de médicament
IN5549CH2012 IN2012CH05549A (fr) 2012-12-31 2013-12-27

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN5549CH2012 IN2012CH05549A (fr) 2012-12-31 2013-12-27

Publications (1)

Publication Number Publication Date
IN2012CH05549A true IN2012CH05549A (fr) 2015-07-03

Family

ID=51019974

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5549CH2012 IN2012CH05549A (fr) 2012-12-31 2013-12-27

Country Status (2)

Country Link
IN (1) IN2012CH05549A (fr)
WO (1) WO2014102745A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502077D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd Improved hme technology
US11510877B2 (en) 2017-10-10 2022-11-29 Capsugel Belgium Nv Gelling multiparticulates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form

Also Published As

Publication number Publication date
WO2014102745A1 (fr) 2014-07-03

Similar Documents

Publication Publication Date Title
WO2015120110A3 (fr) Nouvelles formulations pharmaceutiques
WO2015018380A3 (fr) Nanoparticules thérapeutiques et leurs procédés de préparation
EP3626253A3 (fr) Formulations stables de linaclotide
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
GB2495676A (en) Use of binders for manufacturing storage stable formulations
PH12015501096A1 (en) Composition for immediate and extended release
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
TN2015000135A1 (en) Modified release formulations for oprozomib
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
WO2014056824A3 (fr) Composition de soins de bouche
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
WO2014006636A3 (fr) Compositions stables de fésotérodine
EP2871187A4 (fr) Nouveau composé ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique le contenant à titre de principe actif
IN2012CH05549A (fr)
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
SI2722322T1 (sl) 1,3-di-okso-indenski derivat, farmacevtsko sprejemljiva sol ali optični izomer le-tega, postopek njegov priprave in farmacevtski sestavek, ki ga vsebuje kot protivirusno aktivno sestavino
WO2013072770A3 (fr) Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride
EP2842938A4 (fr) Nouveaux dérivés de bêta-alanine, leurs sels pharmaceutiquement acceptables et composition pharmaceutique les comprenant en tant qu'ingrédient actif
WO2011161223A3 (fr) Formes pharmaceutiques à usage oral comprenant de la lercanidipine et de l'énalapril et leurs sels pharmaceutiquement acceptables